← All trials
NCT05182567
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 23, 2022
- Primary completion
- Dec 31, 2022
- Completion date
- Jun 30, 2023
- First posted
- Jan 10, 2022
- Last posted
- Sep 30, 2022
- Enrollment
- 69
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- GeneOne Life ScienceLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.